PDCD1 and neoplasm: Evaluation of antitumor efficacy of AdV-D24-ICOSL-CD40L, AdV-D24 and the combination therapy with anti PD-1 antibody in murine melanoma B16V allograft immunocompetent C57BL/6 model revealed maximum and significant reduction in tumor volume in mice treated with AdV-D24-ICOSL-CD40L combined with anti PD-1 antibody.